Tega Therapeutics, Inc.
Publicly observedLa Jolla, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | La Jolla | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Tega Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | C1LJLCS3PM51 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant18 Sept 2026Publicly observed
NIH SBIR/STTR award: Activities and Biophysical Properties of Heparins, Engineered to Reduce HIT
USD 498,086.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant5 Aug 2025Publicly observed
NIH SBIR/STTR award: Title: New Clinical Biomarkers for GM1 Gamgliosidosis
USD 500,000.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.